Compare MIND & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIND | PLRX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 79.9M |
| IPO Year | N/A | 2020 |
| Metric | MIND | PLRX |
|---|---|---|
| Price | $8.10 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | 102.0K | ★ 621.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.45 | $1.09 |
| 52 Week High | $14.50 | $1.95 |
| Indicator | MIND | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 65.71 |
| Support Level | $7.91 | $1.12 |
| Resistance Level | $9.27 | $1.43 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 55.15 | 97.30 |
MIND Technology Inc provides technology and solutions for exploration, survey, and defense applications in oceanographic, hydrographic, defense, seismic, and security industries. The company operates in segments namely, Seamap Marine Products and Klein Marine Products helps manufacture and sell specialized, high-performance sonar and seismic equipment. The company generates more revenue from Seamap Marine Products. The company's geographical segments include the United States; China, Norway; Turkey; Singapore; and Canada & Other.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.